By: Yuka Osada On: July 9, 2026 US FDA’s New AEMS Platform: One Dashboard, Millions of Safety Signals
By: Yuka Osada On: June 25, 2026 Can Your Biosimilar Skip Phase 3 Trials? US FDA’s Biosimilar Rules Explained
By: Yuka Osada On: June 18, 2026 From Foreign Phase 1 Studies to U.S. Phase 2: Getting EOP1 Meetings Right
By: Yuka Osada On: December 18, 2025 Japan Clinical Trials Unlocked: PMDA Pre-Consultation to First Patient In
By: Yuka Osada On: September 3, 2025 Fast Track vs. Breakthrough Therapy: Key Clinical Strategy Differences
By: Yuka Osada On: August 13, 2025 Precision Neuroscience Secures FDA Approval: Layer 7-T Device Redefines Clinical-Ready Brain–Computer Interfaces
By: Yuka Osada On: March 19, 2025 Understanding Protocol Deviations for Clinical Investigations in the US
